Efficacy and Safety of Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed After Prior Immune Checkpoint Inhibitors
Latest Information Update: 03 Mar 2026
At a glance
- Drugs Tislelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms FMT-LUNG
Most Recent Events
- 03 Mar 2026 New trial record